Incb057643 (Not yet branded)
Other Medications
Description
INCB057643 is an oral small molecule inhibitor being developed by Incyte Corporation for treatment of advanced solid tumors including colorectal cancer. Based on clinical trial data, this compound targets specific enzymatic pathways involved in tumor immune evasion and has been tested in combination with immunotherapy agents like pembrolizumab. The drug has been evaluated in phase 1 studies as both monotherapy and in combination regimens for patients with advanced malignancies.
Mechanism of Action
INCB057643 functions as a selective inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme that catalyzes the rate-limiting step in tryptophan catabolism along the kynurenine pathway. By blocking IDO1 activity, the drug aims to reduce immunosuppressive metabolites in the tumor microenvironment and enhance T-cell mediated anti-tumor immune responses.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.